Javascript must be enabled to continue!
Empagliflozin Pharmacotherapy: An Updated Overview
View through CrossRef
It has been estimated that by 2030, the number of patients with diabetes is expected to rise to 552 million. Moreover, an estimated 20 million new
cancer cases were reported in 2022, and 64 million people worldwide are currently suffering from heart failure. Recently, there has been an
increasing interest regarding the prescription of a drug that was approved for use in May, 2014, which is called empagliflozin. Up to now, limited
data is available on the efficacy, safety, and side effects of empagliflozin against a variety of diseases, including diabetes, heart failure, and cancer.
Therefore, this study aimed to gather relevant data on empagliflozin by searching electronic databases, such as Web of Science, Scopus, Pubmed,
and Cochrane Library, through October 9th, 2024. One hundred thirty-eight relevant studies, including review articles, clinical trials, and case
reports, were assessed. It was found that orally, once daily use of empagliflozin, in addition to the glucose-lowering effect, suppresses
inflammation and improves diastolic function. Empagliflozin inhibits breast cancer stemness by inactivating transcription factors and enzyme
pyruvate kinase M2 via enhanced miR-128-3p expression. By inhibiting the sodium-glucose cotransporter, the drug has a well-known safety and
efficacy in patients with breast cancer, type 1 or 2 diabetes, acute septic renal injury, renal disease, and heart failure. Regarding efficacy,
empagliflozin acts as an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, sodium-glucose cotransporter type 2 inhibitor,
vascular resistance prevention, and albuminuria-lowering agent. A recently published observational study confirmed the efficacy and safety of
empagliflozin in improving kidney function and glycemic profile and reducing cardiovascular events in diabetic patients with advanced chronic
kidney disease. In addition, empagliflozin is efficient as a blood pressure-lowering agent in patients with hypertension and those at higher risk of
cardiovascular disease. Furthermore, for patients with diabetes and obesity, empagliflozin reduces the progression of kidney disease and improves
clinical conditions in those with high blood pressure. It has a beneficial effect on hemoglobin A1c (HbA1c), body weight, glucose variability, and
total daily insulin use in people with type 1 diabetes. Itching or redness of the genital area, genital infection, hematuria, difficulty in urination,
bladder pain, painful sexual intercourse, peripheral amputations, and Fournier’s gangrene (rarely informed adverse effects) are the most commonly
reported side effects. Additionally, pancreatitis, bad odor, and suicide attempts were recorded in some published case reports. Further evidencebased
polypharmacological benefits studies' of empagliflozin associated with its nephroprotective, cardioprotective, and glucose-lowering effects
and in cancer were reported to be advantageous.
Title: Empagliflozin Pharmacotherapy: An Updated Overview
Description:
It has been estimated that by 2030, the number of patients with diabetes is expected to rise to 552 million.
Moreover, an estimated 20 million new
cancer cases were reported in 2022, and 64 million people worldwide are currently suffering from heart failure.
Recently, there has been an
increasing interest regarding the prescription of a drug that was approved for use in May, 2014, which is called empagliflozin.
Up to now, limited
data is available on the efficacy, safety, and side effects of empagliflozin against a variety of diseases, including diabetes, heart failure, and cancer.
Therefore, this study aimed to gather relevant data on empagliflozin by searching electronic databases, such as Web of Science, Scopus, Pubmed,
and Cochrane Library, through October 9th, 2024.
One hundred thirty-eight relevant studies, including review articles, clinical trials, and case
reports, were assessed.
It was found that orally, once daily use of empagliflozin, in addition to the glucose-lowering effect, suppresses
inflammation and improves diastolic function.
Empagliflozin inhibits breast cancer stemness by inactivating transcription factors and enzyme
pyruvate kinase M2 via enhanced miR-128-3p expression.
By inhibiting the sodium-glucose cotransporter, the drug has a well-known safety and
efficacy in patients with breast cancer, type 1 or 2 diabetes, acute septic renal injury, renal disease, and heart failure.
Regarding efficacy,
empagliflozin acts as an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, sodium-glucose cotransporter type 2 inhibitor,
vascular resistance prevention, and albuminuria-lowering agent.
A recently published observational study confirmed the efficacy and safety of
empagliflozin in improving kidney function and glycemic profile and reducing cardiovascular events in diabetic patients with advanced chronic
kidney disease.
In addition, empagliflozin is efficient as a blood pressure-lowering agent in patients with hypertension and those at higher risk of
cardiovascular disease.
Furthermore, for patients with diabetes and obesity, empagliflozin reduces the progression of kidney disease and improves
clinical conditions in those with high blood pressure.
It has a beneficial effect on hemoglobin A1c (HbA1c), body weight, glucose variability, and
total daily insulin use in people with type 1 diabetes.
Itching or redness of the genital area, genital infection, hematuria, difficulty in urination,
bladder pain, painful sexual intercourse, peripheral amputations, and Fournier’s gangrene (rarely informed adverse effects) are the most commonly
reported side effects.
Additionally, pancreatitis, bad odor, and suicide attempts were recorded in some published case reports.
Further evidencebased
polypharmacological benefits studies' of empagliflozin associated with its nephroprotective, cardioprotective, and glucose-lowering effects
and in cancer were reported to be advantageous.
Related Results
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Empagliflozin in the Real World: Strengthening Heart Failure Care in Pakistan
Heart failure with reduced ejection fraction (HFrEF) remains a major clinical challenge worldwide and is a pressing public health issue in Pakistan. Patients here often present at ...
The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
The Validation and Determination of Empagliflozin Concentration in the Presence of Grapefruit Juice Using HPLC for Pharmacokinetic Applications
Type 2 diabetes mellitus is a multifactorial disorder whose primary manifestation usually initiates with elevated blood sugar levels. Several antidiabetic agents are used to manage...
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure
Background:
In EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) empagliflozin significantly reduced the risk of ...
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia
Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia
Abstract
Background
Empagliflozin reduces the risk of cardiovascular disease (CVD) in patients with type 2 diabetes (T2DM) and high cardiovascular r...
Empagliflozin-Metformin in Hypertension Therapy Synergistically Upregulate 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 and Acetyl-coenzyme A acyltransferase 1B
Empagliflozin-Metformin in Hypertension Therapy Synergistically Upregulate 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 2 and Acetyl-coenzyme A acyltransferase 1B
Background: Combination therapy of Empagliflozin (a Sodium Glucose Transporter 2 Inhibitor) and Metformin (a biguanide) is known to lower Blood Pressure (BP) and is particularly su...
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Efficacy of SGLT2 Inhibitors in Heart Failure to Improve Ejection Fraction
Background: Heart failure with reduced ejection fraction is a major cause of morbidity, hospital admission, and cardiovascular mortality worldwide. Many patients end up with poor f...
The renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure (RECEDE-CHF) trial
The renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure (RECEDE-CHF) trial
Abstract
Introduction
The SGLT2 inhibitors have been shown to reduce heart failure (HF) hospitalisations in patients with Type 2...
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
Aims:
Empagliflozin is a selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor in clinical development for the treatment of type 2 diabetes mellitus. This...

